tbuckley/cabot-search huggingface dataset:
Non-Invasive Multimodal/Multi-Scale Imaging of Bone Marrow Microenvironment Reveals Structural and Functional Heterogeneity in Different Bone Marrow Compartments: Functional Implications On Mouse and Human Hematopoietic Stem Cell Niches in Health and Disease
Authors: Francois Lassailly, Katie Foster, Lourdes Lopez-Onieva, Erin Currie, Dominique Bonnet
Journal: Blood (2012)
Cytogenetic Profile of Plasma Cell Neoplasms with 1q21 (CKS1B) Gains: A Comparative Study Between Cytoplasmic Immunoglobulin (cIg) Fluorescence In Situ Hybridization (FISH) and Conventional FISH Involving 1283 Patients,
Authors: Christine F. Stephenson, Carol S Berger, Lioudmila I Richmond, Jason P Edmiston, Eduardo S. Cantu, Henry Y. Dong
Journal: Blood (2011)
Near Infrared Fluorescent Nanoparticles Derived from Hyaluronic Acid Improve Tumor Contrast for Image-Guided Surgery
Authors: Tanner K. Hill, Sneha S. Kelkar, Nicholas E. Wojtynek, Joshua J. Souchek, William M. Payne, Kristina Stumpf, Frank C. Marini, Aaron M. Mohs
Journal: Theranostics (2016)

Tumor tissue that remains undetected at the primary surgical site can cause tumor recurrence, repeat surgery, and treatment strategy alterations that impose a significant patient and healthcare burden.Intraoperative near infrared fluorescence (NIRF) imaging is one potential method to identify remaining tumor by visualization of NIR fluorophores that are preferentially localized to the tumor.This requires development of fluorophores that consistently identify tumor tissue in different patients and tumor types.In this study we examined a panel of NIRF contrast agents consisting of polymeric nanoparticle (NP) formulations derived from hyaluronic acid (HA), with either physically entrapped indocyanine green (ICG) or covalently conjugated Cy7.5.Using orthotopic human breast cancer MDA-MB-231 xenografts in nude mice we identified two lead formulations.One, NanoICGPBA, with physicochemically entrapped ICG, showed 2.3-fold greater tumor contrast than ICG alone at 24 h (p < 0.01), and another, NanoCy7.5100-H, with covalently conjugated Cy7.5, showed 74-fold greater tumor contrast than Cy7.5 alone at 24 h (p < 0.0001).These two lead formulations were then tested in immune competent BALB/c mice bearing orthotopic 4T1 breast cancer tumors.NanoICGPBA showed 2.2-fold greater contrast than ICG alone (p < 0.0001), and NanoCy7.5100-Hshowed 14.8-fold greater contrast than Cy7.5 alone (p < 0.0001).Furthermore, both NanoICGPBA and NanoCy7.5100-Hprovided strong tumor enhancement using image-guided surgery in mice bearing 4T1 tumors.These studies demonstrate the efficacy of a panel of HA-derived NPs in delineating tumors in vivo, and identifies promising formulations that can be used for future in vivo tumor removal efficacy studies.
An Algorithm Combining Clinical Characteristics and Day 7 Biomarker Concentrations Predicts Future Graft-Versus-Host Disease Following Related Donor Hematopoietic Cell Transplantation
Authors: Andrew C. Harris, James L.M. Ferrara, Thomas M. Braun, Daniel R. Couriel, Sung W. Choi, Carrie Kitko, Steven Goldstein, John M. Magenau, Sophie Paczesny, Attaphol Pawarode, Pavan Reddy, Gregory A. Yanik, Austin Taylor, James Connelly, Craig A. Byersdorfer, John E. Levine
Journal: Blood (2012)
High-Dose Therapy and Autologous Stem Cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma Group
Authors: Roman Hajek, Ivan Spicka, Vladimir Maisnar, Tomas Pika, Evzen Gregora, Lenka Zahradova, Jan Straub, Jakub Radocha, Jiri Minarik, Petr Pavlicek, Marta Krejci, Ludek Pour, Zdenek Adam, Vlastimil Scudla
Journal: Blood (2012)
More than half of stroke patients were not given preventive drugs, study finds
Authors: Susan Mayor
Journal: BMJ (2016)

More than half of patients who have a first stroke or transient ischaemic attack (TIA) do not have lipid lowering, antihypertensive, or anticoagulant drugs prescribed before their event despite one or more of these being clinically indicated for stroke prevention, an analysis of UK primary care data has found.1

Dyslipidaemia, hypertension, and atrial fibrillation are three of the most important risk factors for stroke and TIA. Lipid lowering drugs, antihypertensives, and anticoagulants …
Effects of Vitamin D Receptor Activation and Dietary Sodium Restriction on Residual Albuminuria in CKD: The ViRTUE-CKD Trial
Authors: Charlotte A. Keyzer, G. Fenna van Breda, Marc G. Vervloet, Maarten A. de Jong, Gozewijn D. Laverman, Marc H. Hemmelder, Wilbert M.T. Janssen, Hiddo J. Lambers Heerspink, Arjan J. Kwakernaak, Stephan J.L. Bakker, Gerjan Navis, Martin H. de Borst
Journal: Journal of the American Society of Nephrology (2016)

Reduction of residual albuminuria during single–agent renin-angiotensin-aldosterone blockade is accompanied by improved cardiorenal outcomes in CKD. We studied the individual and combined effects of the vitamin D receptor activator paricalcitol (PARI) and dietary sodium restriction on residual albuminuria in CKD. In a multicenter, randomized, placebo (PLAC)–controlled, crossover trial, 45 patients with nondiabetic CKD stages 1–3 and albuminuria &gt;300 mg/24 h despite ramipril at 10 mg/d and BP&lt;140/90 mmHg were treated for four 8-week periods with PARI (2 μ g/d) or PLAC, each combined with a low-sodium (LS) or regular sodium (RS) diet. We analyzed the treatment effect by linear mixed effect models for repeated measurements. In the intention-to-treat analysis, albuminuria (geometric mean) was 1060 (95% confidence interval, 778 to 1443) mg/24 h during RS + PLAC and 990 (95% confidence interval, 755 to 1299) mg/24 h during RS + PARI ( P =0.20 versus RS + PLAC). LS + PLAC reduced albuminuria to 717 (95% confidence interval, 512 to 1005) mg/24 h ( P &lt;0.001 versus RS + PLAC), and LS + PARI reduced albuminuria to 683 (95% confidence interval, 502 to 929) mg/24 h ( P &lt;0.001 versus RS + PLAC). The reduction by PARI beyond the effect of LS was nonsignificant ( P =0.60). In the per-protocol analysis restricted to participants with ≥95% compliance with study medication, PARI did provide further albuminuria reduction ( P =0.04 LS + PARI versus LS + PLAC). Dietary adherence was good as reflected by urinary excretion of 174±64 mmol Na + per day in the combined RS groups and 108±61 mmol Na + per day in the LS groups ( P &lt;0.001). In conclusion, moderate dietary sodium restriction substantially reduced residual albuminuria during fixed dose angiotensin–converting enzyme inhibition. The additional effect of PARI was small and nonsignificant.
THU0117 Diagnostic Values of anti-Sa and anti-RA33 Antibodies in Rheumatoid Arthritis: A Meta-Analysis
Authors: Y.H. Lee, Y.H. Seo, S.J. Choi, G.G. Song
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti-Sa antibody was identified in 1994 and belongs to a class of antibodies that target citrullinated antigens. Anti-Sa antibody is highly specific for diagnosing rheumatoid arthritis (RA, but it is associated with low prevalence and sensitivity. Anti-RA33 antibody was identified in 1989 and targets RA33 complex or heterogeneous nuclear ribonucleic protein. In contrast to anti-Sa antibody, anti-RA33 antibody does not target citrullinated antigens. Both anti-Sa and anti-RA33 antibodies are considered as specific serological markers for RA. However, studies assessing the diagnostic value of these antibodies in RA have provided inconsistent results. <h3>Objectives</h3> The aim of this study is to evaluate the diagnostic performance of anti-Sa and anti-RA33 antibodies in RA. <h3>Methods</h3> PubMed, Embase, and Cochrane library databases were searched for relevant studies and 2 meta-analyses were performed to determine the diagnostic accuracy of anti-Sa and anti-RA33 antibodies in patients with RA. <h3>Results</h3> The meta-analysis included 17 studies. Of these, 9 studies, which included 1,095 patients and 1,667 controls, were on anti-Sa antibody and 8 studies, which included 905 patients and 835 controls, were on anti-RA33 antibody. Pooled sensitivity and specificity of anti-Sa antibody were 39.5% (95% confidence interval [CI], 36.5–42.4) and 96.8% (95% CI, 95.9–97.4), respectively, and those of anti-RA33 antibody were 31.8% (95% CI, 28.7–35.0) and 90.1% (95% CI, 87.8–92.1), respectively. PLR, NLR, and DOR of anti-Sa antibody were 14.11 (95% CI, 7.076–28.13), 0.607 (95% CI, 0.558–0.703, and 22.76 (95% CI, 11.10–46.69), respectively, and those of anti-RA33 antibody were 3.429 (95% CI, 2.039–5.765), 0.761 (95% CI, 0.681–0.851), and 4.597 (95% CI, 2.602–8.121), respectively. AUC and Q<sup>*</sup> index for anti-Sa antibody were 0.558 and 0.543, respectively, while those for anti-RA33 antibody were 0.501 and 0.500, respectively. <h3>Conclusions</h3> Our meta-analysis indicated that both anti-Sa and anti-RA33 antibodies were highly specific and the PLR of anti-Sa antibody was very useful for diagnosing RA, although they were not sensitive for diagnosing RA. <h3>Disclosure of Interest</h3> None declared
AB1112-HPR Systemic Sclerosis Treatment: An Occupational Therapists' View
Authors: J. Stöcker, C. van den Ende, K. Gevers, P. van Keeken, A. Wilting
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> SSc has a great impact on daily functioning [1]. People with SSc make regular use of allied health care, mainly physiotherapy and occupational therapy (OT), for guidance in coping with the many consequences of the disease. Little is known about the current practice of occupational therapy for people with SSc [2]. <h3>Objectives</h3> The purpose of this qualitative pilot study was to map the experience of Dutch occupational therapists about their daily practice and vision on optimal SSc care through OTs. <h3>Methods</h3> Five female OTs, median age 38.6 years (range 25–46 years) from different work settings and regions with an average work experience of 8.6 years in SSc care, were recruited through the Dutch organisation of Health Professionals in rheumatology. A semi-structured interview was conducted with each participant and transcribed verbatim. Data were analysed by the three-step method of Boeije [3]. <h3>Results</h3> OTs describe that in CURRENT PRACTICE patients report problems on a functional, activity and participation level, while the treatment is mostly aiming at functional level (including aids and compensations). They experience that their work is experience-based due to the lack of available evidence. The nature of interventions is significantly dependent on the phase of disease in which patients are. They experience a low number of referrals in a late state of the disease and suggest that this might be due to the lack of knowledge about occupational therapy. In an OPTIMAL SITUATION OTs are involved earlier in the disease process and focus on training and patient needs. They would want to focus on prevention and education including the social environment of the patient. In order to offer optimal treatment they would want to work guideline-based and establish sustained treatment relationships. Earlier referral in the disease process would enable meaningful treatment. They express their need for a clear OT profile to be known by rheumatologists, to facilitate timely and appropriate referrals to OTs. <h3>Conclusions</h3> We found a distinct difference between current and ideal OT practice. The newly gained knowledge of this study can be used by OTs for a transition from treatment addressing compensation to a treatment targeting activity and participation. More attention should be paid to timely referrals with a transparent indication. <h3>References</h3> Stamm, T., et al. (2011). Concepts of functioning and health important to people with systemic sclerosis: a qualitative study in four European countries. Ann Rheum Dis, 70(6), 1074–1079. Willems, L., et al. (2013). Health care use and patients9 perceptions on quality of care in systemic sclerosis. Clin Exp Rheum, 64. Boeije, H. R. (2014). Analyseren in kwalitatief onderzoek: denken en doen. Den Haag: Boom Lemma. <h3>Disclosure of Interest</h3> None declared
Pre-Transplant Consolidation and Cost Effectiveness of RIC Allogeneic SCT in Patients of AML-CR1 in India
Authors: Abhijeet Ganapule, Shashikant Apte, Navin Khattry, Reetu Ashish Jain, Joseph M John, Sharat Damodar, Lalit Kumar, Dinesh Bhurani, Kavitha M Lakshmi, Rayaz Ahmed, Ranjit Kumar Sahoo, Nataraj K Srinivasarao, Amrith Mathew, Tapan Saikia, Alok Gupta, Sachin Punatar, Kannan Subramani, Aby Abraham, Auro Viswabandya, Alok Srivastava, Biju George, Vikram Mathews
Journal: Blood (2014)
PWE-149 5 Years of A DGH Delivered Regional Double Balloon Enteroscopy (DBE) Service
Authors: S Batchelor, D Mansour, S Deshpande, D Nylander, S Panter
Journal: Gut (2016)

<h3>Introduction</h3> Double Balloon Enteroscopy (DBE) allows visualisation and interventional therapy throughout the small bowel. It was commenced in South Tyneside District Hospital (STDH) in January 2010 to complement the existing capsule endoscopy service. <h3>Methods</h3> Records were examined retrospectively for all DBEs at STDH between 1/1/2010 &amp; 31/12/2015 to determine the indication, route &amp; depth of insertion, findings &amp; therapies performed &amp; the complications. <h3>Results</h3> 92 procedures were performed from 172 referrals: (47%) via oral route, (52%) via anal route and (1%) via ileostomy. Procedures were done under conscious sedation or propofol, with GA for planned therapeutic cases. The average depth of insertion for the oral route was 174 cm &amp; 96 cm for the anal route. The overall average insertion time was 71 minutes. (61%) had tattoo applied. The indications were to evaluate suspected or confirmed Crohn’s disease (38%), obscure mid gastrointestinal (GI) bleeding (28%), suspected malignancy or abnormal imaging (20%), detect polyps in suspected or confirmed polyposis syndrome (7%) and refractory coeliac (1%). 25% of patients had more than one indication for DBE. DBE findings: 50% had normal examinations, 11% Crohn’s disease, 16% non-specific inflammation, 10% polyps, 4% tumours and 1% coeliac disease. Other diagnoses included small bowel angioectasia and radiation enteritis. The overall diagnostic yield was 50%. The diagnostic yield for suspected Crohn’s disease was 29%, evaluation of obscure mid GI bleeding was 31%, suspected polyps was 40%, refractory Coeliac was 100% and the evaluation of malignancy and abnormal imaging was 11%. 95% of patients who had a normal DBE had prior abnormalities in their imaging. Limitations: 10 procedures were incomplete due to equipment failure (5), persistent looping (4) &amp; inability to pass strictures (1). 1 was abandoned due to poor bowel preparation. Therapy was performed in 13 (14%) procedures: 3 dilatation of strictures, 5 had Argon Plasma Coagulation, 4 polypectomies and 1 had a bleeding ulcer clipped. No complications were recorded at DBE for any patients <h3>Conclusion</h3> Our DBE service is safe and complements other imaging modality. Our overall diagnostic yield is 50%. Our main indication for DBE is to evaluate suspected Crohn’s (38%) rather than for obscure GI bleeding as in the literature.<sup>1</sup> Even with stringent case selection the diagnostic yield for DBE was lower than the preceding VCE. <h3>Reference</h3> 1 Seong Ran, <i>et al</i>. Changes over time in indications, diagnostic yield, and clinical effects of double-balloon enteroscopy. <i>Clin Gastroenterol Hepatol</i> 2012;<b>10</b>(10):1152–1156. <h3>Disclosure of Interest</h3> None Declared
Impact of Immunophenotype and Cytogenetics in Early Assessment of Post Induction Response in Acute Myeloid Leukemia (AML)
Authors: Robert Schneidewend, Karen B. Carlson, Ehab Atallah, Laura C. Michaelis, Paul R. Hosking, Parameswaran Hari, Mehdi Hamadani, Anita D'Souza, Timothy S. Fenske, Marcelo C. Pasquini, Christopher R. Chitambar, Renju V. Raj, Kimberli Johnston, Amber Essenmacher, Felicia Zook
Journal: Blood (2015)
Cost Effectiveness of Tyrosine Kinase Inhibitor (TKIs) Therapy in Chronic Myelogenous Leukemia (CML) in Comparison to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Based on the Nationwide Inpatient Sample (NIS) Database from 2002 to 2011
Authors: Indumathy Varadarajan, Parshva Patel, Ravindra Sangitha, Kristine Ward, Maneesh Jain, Michael Styler
Journal: Blood (2015)
SAT0602 Is A Brief Education Intervention Effective To Motivate Patients To Stop Smoking?
Authors: R. Tekkatte, L. Williamson, E. Price, S. Carty
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Smoking has been associated with an increased risk of developing rheumatoid arthritis (RA), more severe disease and poor response to disease modifying drugs (DMARD). Motivation is the most important aspect of giving up smoking and also awareness of its ill-effects, self-confidence and support. <h3>Objectives</h3> We have looked at the immediate effect on patient motivation to stop smoking by creating awareness of its ill-effects. <h3>Methods</h3> We surveyed Rheumatology outpatients with an anonymous questionnaire including demographics, smoking status, education status, employment status and awareness of the ill-effects of smoking. Motivation to stop smoking was assessed by 10cm Visual analogue scale (VAS) before and after receiving information on adverse effects of smoking on RA. The information provided was about increased risk of RA, severe disease and poor response to DMARD. <h3>Results</h3> 100 unselected patients completed the questionnaire: 74% female; 46% RA; 22% current smokers; 37% never smokers; 41% ex-smokers. 68% of patients in all categories had attended secondary school. A higher proportion of never smokers had attended University compared with current smokers [20% (8/37) vs. 5% (1/22)]. A higher proportion of current smokers were unemployed as compared with never smokers [32% (7/22) vs. 8% (3/37)]. 50% of patients stated that they had never asked about smoking during consultations. When asked how important smoking is in arthritis, 55% of all patients scored &gt;8/10 on a VAS (0=not bad /10=very bad). There was no significant difference in understanding the importance of smoking on arthritis between current smokers (VAS mean; SD 7.06; 2.35) and never smokers (VAS mean; SD 7.37; 2.15) (p=0.115) and between current smokers and ex-smokers (Mean; SD 7.74; 1.87) (p=0.23). 73% (16/22) of current smokers motivation to give up smoking score increased after they were given information on adverse effects of smoking on RA (mean VAS 4.43 before; 5.79 after) (p=0.03). 27% (6/22) did not change, none decreased. 50% (11/22) of patients felt lack of support and help prevented them stopping smoking. Preferred methods for smoking cessation help were: leaflets 41%; verbal advice 9%; GP review 18%. 54% (22/41) of ex-smokers were happy to speak to the current smokers to provide tips on stopping smoking. <h3>Conclusions</h3> This small study suggests that brief educational intervention may help motivate patients to give up smoking. Lack of support is a common difficulty patients perceive when they try to give up smoking. As RA outcomes are worsened by smoking, clinicians need to be more proactive about promoting smoking cessation. Outpatient appointments provide a good opportunity for this. <h3>Disclosure of Interest</h3> None declared
Documented Infection Load In Patients with Neutropenia; a Survey From the Italian Registry of Neutropenias
Authors: Francesca Fioredda, Michaela Calvillo, Sonia Bonanomi, Fabio Tucci, Piero Farruggia, Anna Pusiol, Roberta Ghilardi, Baldassarre Martire, Elena Mastrodicasa, Angelica Barone, Ilaria Caviglia, Marianna Caso, Elio Castagnola, Carlo Dufour
Journal: Blood (2011)
Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Authors: Sven De Vos, Richard R. Furman, Jacqueline C. Barrientos, Nina D. Wagner-Johnston, Ian Flinn, Jeff P. Sharman, Thomas Boyd, John P. Leonard, Roger Dansey, Yeonhee Kim, Leanne M. Holes, Ronald L. Dubowy, Steven E. Coutre
Journal: Blood (2013)
Mesenchymal Stromal Cells Derived from Human Non-Small Cell Lung Cancer, Normal Lung Tissue, and Bone Marrow: Differences in Frequency, Cytogenetics, Proliferation Behavior, and Chemosensitivity - Implications for Cancer Therapy.
Authors: Sandra Gottschling, Michael Meister, Anna Jauch, Ulf C. Krause, Anja Seckinger, Hans Hoffmann, Hendrik Dienemann, Ho D. Anthony, Michael Thomas
Journal: Blood (2007)
NIMG-11RADIOMIC SUBCLASSIFICATION OF GLIOBLASTOMA
Authors: Rivka Colen, Masumeh Hatami, Aikaterini Kotrotsou, Ahmad Chaddad, Ali Bakhtiari, Markus Luedi, Pascal O. Zinn
Journal: Neuro-Oncology (2015)

BACKGROUND: To identify clinically relevant glioblastoma (GBM) sub-classification/subtypes based on radiomic analysis. Integrated genomic analysis has already identified genomic subtypes of GBM as characterized by specific genomic aberrations and mutations. In our study, we seek to demonstrate a GBM sub-classification based on radiomic texture analysis that is both predictive and prognostic. METHODS: We retrospectively identified 80 GBM treatment naive patients from the Cancer Genome Atlas with corresponding MRI data in the Cancer Imaging Archive. We applied texture analysis (528 features) to each tumor. We extracted texture features and performed feature selection. Univariate and multivariate analysis were also performed. Clustering identified radiomic subclasses. RESULTS: Multiple texture features were associated with GBM and we were able to classify GBM into 4 subtypes. However, subclassification into 3 subclasses were associated with differences in patient progression free and overall survival. CONCLUSIONS: GBM subtypes based on radiomic texture signatures were identified that were both predictive and prognostic. These findings are important as this can help determine patient outcome based on imaging (obtained at the time of diagnosis before treatment); this can also help determine response to therapy at the pre-treatment stage to stratify patients and serve as imaging endpoints for clinical trials.
Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia
Authors: Shan Lin, Roger T. Luo, Anetta Ptasinska, Jon Kerry, Salam A. Assi, Mark Wunderlich, Toshihiko Imamura, Joseph J. Kaberlein, Ahmad Rayes, Mark J. Althoff, John Anastasi, Maureen M. O’Brien, Amom Ruhikanta Meetei, Thomas A. Milne, Constanze Bonifer, James C. Mulloy, Michael J. Thirman
Journal: Cancer Cell (2016)
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study
Authors: Paul Richardson, Sagar Lonial, Andrzej Jakubowiak, Sundar Jagannath, Noopur S Raje, David Avigan, Irene M Ghobrial, Robert L Schlossman, Amitabha Mazumder, Nikhil C Munshi, David H Vesole, Robin Joyce, Deborah Doss, Diane L Warren, Stephen W Hayes, Sarah Kaster, Carol Delaney, Marisa Lauria, Constantine Mitsiades, Teru Hideshima, Robert D. Knight, Dixie-Lee Esseltine, Kenneth C Anderson
Journal: Blood (2008)
H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia
Authors: Ashley Pandolfi, Boris Bartholdy, Masahiro Kawahara, Laura Barreyro, Britta Will, Robert Stanley, Roth Michael, Ujunwa Cynthia Okoye-Okafor, Tihomira I Todorova, Maria E. Figueroa, Ari Melnick, Constantine S. Mitsiades, Ulrich Steidl
Journal: Blood (2012)
Efficacy and Toxicity of FLAI vs ICE for Induction Treatment of Newly Diagnosed AML Patients, Younger Than 60 Years.
Authors: Domenico Russo, Michele Malagola, Giovanni Martinelli, Daniela Damiani, Alessandro Isidori, Antonio De Vivo, Giuseppe Visani, Anna Candoni, Angela Michelutti, Renato Fanin, Pier Paolo Piccaluga, Alessandro Bonini, Paolo Avanzini, Luigi Gugliotta, Eliana Zuffa, Alfonso Zaccaria, Daniela Raspadori, Monica Bocchia, Francesco Lauria, Giancarla Pricolo, Patrizio Mazza, Ivana Pierri, Marco Gobbi, Michele Baccarani
Journal: Blood (2004)